Myelodysplastic Syndromes 2023: What’s New Presentations
ASH Friday Satellite Symposium
December 8, 2023

ACTIVITY OVERVIEW

The 2023 Symposium focused on recent advances in the diagnosis, classification and management of patients with myelodysplastic syndromes (MDS). The program combines recent data, application of new tools and evidence on current practice with information that might be applied in the future.

PRESENTATIONS

Click the titles below to view the presentations

The Foundation appreciates the ongoing support from Astex Pharmaceuticals Inc, BMS, Geron Corporation, Notable, and Taiho Oncology Inc.

TARGET AUDIENCE

This activity is designed for an audience of pharmacists, physicians, physician assistants and nurses.

LEARNING OBJECTIVES

Upon completion of the educational activity, participants should be able to:

• Identify and articulate the major challenges faced in the fields of diagnosis, prognosis, and therapy in MDS.
• Identify the key diagnostic criteria used in various MDS classification systems, including factors such as bone marrow morphology, cytogenetics, and clinical parameters.
• Assess the clinical implications of diagnosing pre-MDS states, including the need for regular monitoring, patient education, and informed decision-making regarding treatment options.
• Review the concept of lower-risk myelodysplastic syndromes (LR-MDS), including the clinical and hematological characteristics that define this subgroup.
• Explore various AI applications in MDS practice, such as risk stratification, diagnosis, treatment response prediction, and personalized treatment recommendations.
• Explore the importance of tailoring treatment approaches to individual patients, especially in the case of higher risk diseases.
• Review relevant clinical studies and trials that investigate the impact of cytoreduction on transplant outcomes.
• Utilize critical thinking skills to prioritize potential diagnoses, ruling them in or out systematically using clinical reasoning.

FACULTY

Moshe Mittelman, MD – Symposium Co-Chair

Professor of Medicine
Department of Medicine
Tel-Aviv Sourasky Medical Center
Tel-Aviv University Medical School
Tel-Aviv, Israel

Rena Buckstein, MD – Symposium Co-Chair

Associate Professor, Department of Medicine
Odette Cancer Center
Toronto, Ontario, Canada

Stephen Nimer, MD – MDSF Chairman

Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, Florida, USA

Mario Cazzola, MD

Professor of Hematology
Fondazione IRCCS Policlinico San Matteo
University of Pavia
Pavia, Italy

Jane Churpek, MD

Assistant Professor
University of Wisconsin School of Medicine and Public Health
Carbone Cancer Center
Madison, Wisconsin, USA

Matteo Della Porta, MD

Humanitas Research Hospital, & Humanitas University
Rozzano Milan, Italy

Guillermo Garcia-Manero, MD

McCredie Professor of Medicine
Vice Chair, Department of Leukemia
Chief, Section of MDS
The University of Texas MD Anderson Cancer Center
Houston, TX, USA

Aristoteles Giagounidis, MD

The University of Texas MD Anderson Cancer Center
Houston, TX, USA

Christopher Gibson, MD

Dana Farber Cancer Institute
Boston, MA, USA

Aziz Nazha, MD

Thomas Jefferson University
Philadelphia, PA, USA

Uwe Platzbecker, MD

Director
Medical Clinic and Policlinic 1
Hematology and Cellular Therapy
University Hospital Leipzig
Leipzig, Germany

Michael R. Savona, MD

Professor of Medicine and Cancer Biology
Vanderbilt University School of Medicine
Nashville, Tennessee, USA

Lewis Silverman, MD

Icahn School of Medicine at Mount Sinai
Director Translational Research Center for the Myelodysplastic Syndrome
Tisch Cancer Institute
New York City, New York, USA